Response to Acute Exercise in Eating Disorders

April 30, 2026 updated by: University of Wisconsin, Madison

Characterizing Acute Exercise Response in Restrictive Eating Disorders

Individuals with eating disorders (ED) represent a high-priority clinical population, with among the highest mortality rates of any psychiatric disorder, and driven exercise (DEx) is a symptom evidenced in up to 80% of those with EDs that increases impairment and negatively impacts treatment outcome. This study will develop tasks to characterize cognitive, affective, and biological response to exercise among adolescent and young adult females with EDs and determine whether acute exercise response associates with free-living activity and DEx. This R21 project will provide foundational data to guide research and development of treatments that are more precisely targeted to the symptom of driven exercise and to ultimately improve clinical outcomes associated with EDs.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Eating disorders (EDs) are among the deadliest of all psychiatric disorders. However, first-line treatments for EDs are effective for only roughly 40% of adolescent patients. One barrier to treatment efficacy is the persistence of driven exercise (DEx; exercising in a compulsive manner to control weight and/or regulate emotion), a hallmark symptom reported among many adolescents diagnosed with restrictive EDs (59-73%). Among other negative sequelae, DEx is associated with suicidal behavior, poorer treatment outcome, increased comorbid psychopathology, and risk for relapse. Further, while multiple eating-related tasks have been validated that discriminate between individuals with EDs and healthy populations, there are currently no well-validated tasks that directly assess sensitivity and responsivity to exercise in ED populations. As DEx is a poorly understood symptom that plays a key role in ED maintenance, investigating its biobehavioral underpinnings is of critical importance. Existing research points towards both reward and threat functions of exercise, which may drive and perpetuate DEx among those with EDs. Evaluation of both reward and threat functions of exercise among those with EDs will improve mechanistic understanding of this ED feature; ultimately, improved understanding of DEx will inform treatment targets. The proposed project will recruit adolescent and young adult females (16-25y) with (n = 67) and without (n = 33) EDs from two sites to participate in a comprehensive evaluation of acute exercise response. The current project will 1) characterize variability in biobehavioral response to in-lab exposure to moderate-intensity exercise among those with and without EDs; 2) create and refine tasks that capture engagement of reward- and threat-related systems during exercise; and 3) test hypotheses that acute exercise response is more pronounced among individuals with EDs and that acute exercise response relates to ED symptom severity, DEx, and free-living activity. Detailed explication of acute exercise effects among individuals with EDs in a controlled setting will have significant impact on the empirical study of EDs, specifically to (i) improve assessment of DEx risk and function (ii) elucidate a testable model of DEx risk and (iii) suggest targets for DEx intervention. The methods validated in this project will improve understanding of DEx, a treatment- resistant ED feature. These methods will also lay the groundwork for larger-scale, clinical research which clarifies optimal targets for DEx in ED treatment.

Study Type

Interventional

Enrollment (Actual)

74

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94158
        • University of California San Francisco
    • Wisconsin
      • Madison, Wisconsin, United States, 53719
        • University of Wisconsin-Madison

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Aged 16-25
  • ED participants must meet full criteria for DSM-5 restrictive-spectrum eating disorders characterized by weight and shape concern, I.e., anorexia nervosa (AN); mild, moderate, or in partial remission), atypical AN, and OSFED -AN type only)
  • ED participants must be medically stable, and suitable for outpatient treatment
  • Biological Females, Assigned Female at birth
  • English Speaking

Exclusion Criteria:

  • Those with a medical condition that precludes exercise (e.g., severe asthma) will be excluded for any contraindications

    • Biological Males, Assigned Male at birth
    • BMI less than 16 (over 18 years) or less than 75% expected body weight (under 18 years)
    • Reported intake on Eating Disorder Examination <1000kcal daily
    • Current purging >1x per day
    • Current regular episodes of objective binge eating (>1x/wk)
    • Current self-report of loss-of control eating per the Eating Disorders Examination Interview
    • ED related hospitalization, partial hospitalization, or residential treatment in the past month
    • Any endorsed medical concerns related to physical activity (as probed in the phone screening questions regarding cardiovascular, pulmonary, or metabolic disease).
    • Major medical disorders (e.g., cancer, AIDS)
    • Physical discomfort or difficulty with blood draws
    • Psychotic disorders
    • Intellectual disabilities
    • Developmental disorders
    • Active substance use disorder
    • Current suicidal risk per the Ask Suicide Screening Questionnaire
    • Pregnancy
    • Psychiatric medications that have not been stable for at least 4 weeks
    • Acute sedatives / pain killers (e.g., benzodiazepines, opioids) and prescription stimulants (e.g., methylphenidate, amphetamines) are not permitted for the full day prior to the laboratory session. The noted short-term medication holds only apply to subjects taking the noted medications in cases used to treat ADHD or other psychiatric conditions
    • Resting heart rate <50 beats per minute (assessed at screening visit)
    • Low blood pressure (<90/60), (assessed at screening visit)
    • Daily cannabis use
    • History of light headedness or fainting during blood draws or physical activity
    • History of chest pain during physical activity
    • Bone, joint, cardiac, pulmonary, metabolic, or other medical conditions that may be worsened by physical activity (e.g., COPD, diabetes, hypertension) that are not currently addressed via medication or lifestyle change.
    • Physical disabilities that prohibit task performance (such as blindness or deafness)
    • Any other condition that the investigator believes might put the participant at risk for negative outcomes
    • Individuals with a restrictive eating disorder presentation that does not include weight and shape concern (ARFID) or that has primary binge eating (bulimia nervosa)
    • Indication of health risk associated with exercise on the Physical Activity Readiness Questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Response to Exercise and Rest
Study participants undergo Prescribed Exercise, Self-Paced Exercise, and Rest conditions over the course of 3 study days
Other: Biobehavioral Response to in-lab exposure to physical activity
ED severity, biological and affective markers of physical activity response, and both exercise-specific and general positive (reward) and negative (avoidance/escape) valence sensitivities associate with physical activity will be comprehensively examined.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Response to in-lab exercise - body image
Time Frame: Every 5 minutes during 30 minute bout of activity . There is no follow up beyond the study day itself.
the Body Image States Scale is a 6-item scale that asks participants to report on their momentary body satisfaction on a 9-point Likert scale. Each item begins with the sentence "Right now, I feel" [for instance: "Right now, I feel (Extremely dissatisfied to Extremely satisfied) with my physical appearance"]
Every 5 minutes during 30 minute bout of activity . There is no follow up beyond the study day itself.
Response to in-lab exercise - affect
Time Frame: Every 5 minutes during a 30 minute bout of activity. There is no follow up beyond the study day itself.
Participants self-report items representing the highest loading items from the Physical Activity Affect Scale (PAAS) every 5 minutes during exercise. These items include feeling 'Crummy', 'Enthusiastic', 'Fatigued' and 'Calm'. Participants rate each item using a 5-point scale (0=do not feel-4=feel very strongly).
Every 5 minutes during a 30 minute bout of activity. There is no follow up beyond the study day itself.
Response to in-lab exercise - biomarkers
Time Frame: pre-exercise (Baseline), post-exercise (30 minutes), pre-rest (Baseline), post-rest (30 minutes). There is no follow up beyond the study day itself.

Biomarkers will be collected via blood samples taken before and after exercise and rest and measured via Enzyme-linked immunosorbent assay (ELISA) kits :

circulating leptin (leptin immunoassay) circulating endocannabinoids (2-arachidonoylglycerol (2-AG) and 2-oleoylglycerol (2-OG) plasma-based immunoassays) circulating brain-derived neurotrophic factor (BDNF immunoassay) circulating cortisol (Cortisol immunoassay)
pre-exercise (Baseline), post-exercise (30 minutes), pre-rest (Baseline), post-rest (30 minutes). There is no follow up beyond the study day itself.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Wisconsin, Madison

Collaborators

National Institute of Mental Health (NIMH)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 2, 2023

Primary Completion (Actual)

July 31, 2025

Study Completion (Actual)

July 31, 2025

Study Registration Dates

First Submitted

January 9, 2024

First Submitted That Met QC Criteria

January 18, 2024

First Posted (Actual)

January 19, 2024

Study Record Updates

Last Update Posted (Actual)

May 5, 2026

Last Update Submitted That Met QC Criteria

April 30, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019-1585
  • 1R21MH131787-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Project publications will provide full information about procedures and analyses to enable replication. We will share data and code on an institutional webpage for reproducibility.

IPD Sharing Time Frame

At study conclusion

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Eating Disorders

Clinical Trials on Biobehavioral Response to in-lab exposure to physical activity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe